UBS Adjusts HUTCHMED Target Price to HK$29.5, Maintains Buy Rating

Stock News08-03 11:33

UBS has released a research report noting that HUTCHMED (00013)'s first-half revenue increased by 0.2% year-on-year, broadly in line with the bank's expectations. Revenue from its oncology and immunology business grew 13% year-on-year, outperforming projections. Net profit for the period was $15.9 million, compared to $455 million in the same period last year, which was primarily due to the recognition of a one-time gain from the sale of a joint venture with Shanghai Pharmaceuticals during the prior period.

The bank has postponed its milestone expectations for AstraZeneca to 2027 and revised its expense forecasts. This has led to a downward adjustment of its 2026 earnings per share estimate, while the 2027 forecast has been increased from $0.06 to $0.08. Consequently, UBS has lowered the target price for HUTCHMED from HK$29.7 to HK$29.5, while maintaining a "Buy" rating.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment